Envision Pharma Group Hires Industry Leader to Oversee the Expansion of Its Japan Asia-Pacific Regional Business Development and Meet Growing Customer Demand Across the Globe

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) — Envision Pharma Group (Envision) has appointed Pauline Bernard to the position of Regional Head, Commercial Strategy, Japan Asia-Pacific (JAPAC). Pauline will help drive Envision’s global leadership as a technology-enabled commercialization, data analytics, and integrated medical capabilities and solutions partner to the life sciences industry. In her new position, […]

Jowin, the Apple in Korea’s cancer treatment, expands their business globally

Jowin Shinhan Securities IPO Korea’s innovative venture company Jowin declares its expansion into the global cancer care market through the establishment of a global telemedicine platform. A telemedicine platform for overseas patients with stage 4 and terminal cancer will be launched in the first half of this year. It will provide remote, non-face-to-face treatments to […]

Jowin, the Apple in Korea’s cancer treatment, expands their business globally

Jowin Shinhan Securities IPO Korea’s innovative venture company Jowin declares its expansion into the global cancer care market through the establishment of a global telemedicine platform. A telemedicine platform for overseas patients with stage 4 and terminal cancer will be launched in the first half of this year. It will provide remote, non-face-to-face treatments to […]

Philips continues to demonstrate strong commitment to its ESG ambitions

February 21, 2023 1.81 billion lives improved by Philips’ health technology products, services and solutions Philips became the first health technology company to obtain approval by the Science Based Targets initiative (SBTi) for its entire value-chain CO2 emissions reduction targets, including Scope 1-3 Continued recognition for sustainability leadership – received CDP’s ‘A List’ rating for […]

Philips continues to demonstrate strong commitment to its ESG ambitions

February 21, 2023 1.81 billion lives improved by Philips’ health technology products, services and solutions Philips became the first health technology company to obtain approval by the Science Based Targets initiative (SBTi) for its entire value-chain CO2 emissions reduction targets, including Scope 1-3 Continued recognition for sustainability leadership – received CDP’s ‘A List’ rating for […]

Philips publishes its Annual Report 2022

February 21, 2023 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2022. Philips’ Annual Report 2022 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 9, 2023. The convocation notice and the agenda, […]

Philips publishes its Annual Report 2022

February 21, 2023 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2022. Philips’ Annual Report 2022 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 9, 2023. The convocation notice and the agenda, […]

Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study

SHANGHAI, China, Feb. 20, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“TORCHLIGHT Study”, NCT04085276) examining the company’s product toripalimab in combination with paclitaxel for injection (albumin-bound) in […]

Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study

SHANGHAI, China, Feb. 20, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“TORCHLIGHT Study”, NCT04085276) examining the company’s product toripalimab in combination with paclitaxel for injection (albumin-bound) in […]